ENTEROBACTER SEPTICEMIA

The steady increase in the incidence of Enterobacter septicemia and th e rapid acquisition by this organism of beta-lactam resistance pose ma jor therapeutic challenges, Enterobacter septicemia is often nosocomia l, At least one other organism is also present in 18% to 50% of cases, The lead point is often a respiratory or venous focus, Most cases occ ur in patients with critical conditions treated in intensive care unit s. Beta-lactamase-producing strains are becoming increasingly common ( as a result of induction or derepression. Antimicrobials should be sel ected based on stability to beta-lactamases.